Zydus Lifesciences shines on getting final approval from USFDA for Acetaminophen injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 437.25, up by 7.75 points or 1.80% from its previous closing of Rs. 429.50 on the BSE.
The scrip opened at Rs. 430.00 and has touched a high and low of Rs. 439.85 and Rs. 430.00 respectively. So far 689 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 511.90 on 29-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 439.85 and Rs. 410.60 respectively. The current market cap of the company is Rs. 43474.17 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Acetaminophen Injection, 1,000 mg/100 mL (10 mg/mL) single-dose vials. Acetaminophen injection is indicated to relieve mild to moderate pain and to reduce fever. It is also used in combination with opioid (narcotic) medications to relieve moderate to severe pain. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.
Acetaminophen injection had annual sales of $72 million in the United States according to IQVIA data (IQVIA MAT Aug 2022). The group now has 330 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
